CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
midazolam intravenous infusion +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03813121
NCT03813121Phase 2Completed
CompareCT.gov

The Effects of Sedatives on Tobacco Use Disorder

Wake Forest University Health Sciences·interventional·Posted Jan 23, 2019·Updated Oct 6, 2022

In Brief

A Phase 2 clinical trial evaluating midazolam intravenous infusion, placebo intravenous infusion, and 1 other intervention for Tobacco Use Disorder. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This proposal will obtain preliminary data on the effect of a single sub-anesthetic dose of a sedative on cigarette craving and smoking behavior as well as measuring tolerability and acceptability.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 23, 2019
Enrollment StartJun 1, 2019
Primary CompletionAug 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.4 years ago

Interventions

midazolam intravenous infusiondrug

Participants will receive a single drug infusion

placebo intravenous infusiondrug

Participants will receive a single placebo infusion

ketamine intravenous infusiondrug

Participants will receive a single drug infusion